Schizophrenia In-Vitro Disease Models

Contact us for further information!

Exploring Schizophrenia Through Advanced In-Vitro Models

Schizophrenia, a complex disorder affecting 1% of the population, presents challenges in treatment, particularly in addressing negative symptoms and cognitive impairments. Traditional approaches have focused on managing positive symptoms, leaving significant therapeutic gaps. At our forefront is pioneering research in developing innovative in-vitro disease models to accelerate breakthroughs in schizophrenia drug discovery.

Our Approach

Drawing on cutting-edge neuroscience, we focus on functional phenotypic in-vitro assays. These models leverage neuronal cell cultures on microelectrode arrays, challenged by disruptive agents like the Neisseria gonorrhoeae, NG, antibody. This novel approach mirrors critical neurodevelopmental processes implicated in schizophrenia, providing a platform to dissect disease mechanisms at a cellular level. NeuroProof demonstrated in this assay links between electrophysiological activity patterns in a dish to clinical markers of schizophrenic patients as a disturbing of the excitatory/inhibitory balance- short the E/I balance and activity patterns that correlate with the theta-band oscillations which are increased in schizophrenic patients.

Advantages of Our Models

Unlike traditional models, our assays offer a nuanced understanding of schizophrenia's complex neural dynamics. By analyzing electrical activity patterns using proprietary methodologies, we identify distinct phenotypic changes induced by our experimental perturbations. This enables targeted screening for compounds capable of reversing these aberrant patterns, promising new avenues for therapeutic intervention.

Innovative Insights

Acknowledging schizophrenia's multifactorial origins—including genetic predispositions and neuroimmunological influences—we integrate developmental and immunological perspectives into our assays. This holistic approach mirrors recent findings implicating maternal immune activation and other environmental factors in disease onset.

Collaborate with Us

Explore our comprehensive screening services tailored for schizophrenia and related disorders. From initial assay development to compound screening campaigns, NeuroProof offers integrated solutions to propel your research forward. Contact us to learn more about how our advanced models can accelerate your path to discovery.

Our Models

PCP - Model

Phencyclidine is a compound provoking psychogenic behavior in humans.

Poly(I:C) model

The viral mimetic peptide Poly(I:C) disturbs maternal immune activation at the TLR3 pathway. 

NG-Model

The NG-model is acting on the TLR4 pathway.

Key Points to Highlight

• Focus on innovative in-vitro disease models for schizophrenia research.
• Utilization of neuronal cell cultures on microelectrode arrays with disruptive agents to test new generations of antipsychotics.
• Analysis of electrical activity patterns to identify phenotypic changes.
• Integration of developmental and neuroimmunological insights.
• Comprehensive screening services and collaborative opportunities are available.